---
run_id: halo-evidence-vs-diagnosis-validation-v8-generic-advice-prompted-02
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v8
benchmark_version: halo-evidence-vs-diagnosis-validation-v8-v1
model_condition: generic_advice_prompted
run_number: 2
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 205
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
condition_packet_sha256: 5e94f3c66f0dff57d38dd5c747b6fa04e65a3365ab875d68633add0ce68b4ce2
output_file: model-outputs/generic_advice_prompted-02.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 02)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v8-v1`, condition `generic_advice_prompted`, run 2 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 205, on the frozen condition packet.

## Output

I recommend that you advise the CEO to commit to the **targeted evidence pass**.

### The Reasoning
Your company is currently experiencing a "false positive" in its growth metrics. The upbeat story in the board packet is built on lagging indicators and artificial stimulants, while the leading indicators are flashing red.

1.  **The Revenue Mirage:** 72% of your expansion revenue is tied to six-month discounts. This is not "market wedge" revenue; it is "bought" revenue. You have effectively paid your customers to renew early. Once those discounts expire, you will face a massive renewal cliff if the product value hasn't actually increased.
2.  **The Usage Gap:** A 44% increase in usage sounds great, but the distribution is skewed. Your "champions" (admins) are using the tool for reporting and enablement, while the "front-line reviewers" (the actual users) are abandoning it at a rate of 69% after one week. In B2B workflow software, if the end-user abandons the tool, the account is a churn risk, regardless of what the champion says in a quote.
3.  **The Compliance Failure:** The abandonment in state-regulated insurance accounts is the most critical signal. In compliance, "explainability" is not a feature—it is the core requirement. A tool that provides a result that cannot be defended to an auditor is not just useless; it is a liability.
4.  **The Cultural Red Flag:** The fact that "why did it choose this?" tickets are being reclassified as "training questions" suggests a systemic effort to mask product deficiency as user ignorance. This is a classic precursor to a product failure.

Scaling broadly (Option 1) would be a catastrophic misallocation of capital. You would be hiring implementation teams to deploy a product that front-line users hate and auditors reject. Narrowing the focus (Option 3) is tempting, but you don't yet have enough evidence to know if "auditor explainability" is the *only* problem, or if the tool's core logic is fundamentally flawed across all segments.

### The Tradeoffs
By choosing the evidence pass, you are sacrificing **short-term momentum and optical growth**. You will have to tell the CEO (and potentially the board) that the "upbeat story" is premature. You are trading the "revenue-led annual plan" for a "product-led validation plan." This means no quota expansion and no aggressive hiring for implementation—which will frustrate the Sales leadership who believe they have found a "wedge."

### The Strongest Reason Against This Recommendation
**The Momentum Trap.** In many mid-market B2B companies, there is a powerful psychological drive to "strike while the iron is hot." The CEO and Sales leadership are currently riding a high of positive quotes and rising NRR. Recommending a "pause" to instrument behavior and stop discounts can be perceived as being "too academic," "risk-averse," or "slowing down the engine" just as the company has found its stride. You risk losing political capital by being the person who "killed the vibe" of the board packet.

### Observable Evidence That Would Change My Mind
I would pivot to **Option 1 (Scale Broadly)** if you could provide evidence of **"Forced Adoption Value."**

Specifically: If the "compliance operations champions" are not just running samples, but are actively rewriting the company's Standard Operating Procedures (SOPs) to mandate the use of Review Assist, and those mandates are resulting in a measurable decrease in "Time to Close" for cases *without* an increase in error rates. If the champions are successfully forcing the front-line reviewers to use the tool and the reviewers are finding it indispensable despite the initial friction, then the 31% retention rate is a temporary onboarding hurdle rather than a fundamental product failure. In that specific case, scaling would be the correct move.
